Observational studyBrain and behavior2025
Serum Nrf2 Levels in Severe Traumatic Brain Injury Patients and Its Significance in Predicting 28-Day Mortality.
Observational study in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Relevance of cerebral microbleeds with leaky blood brain barrier in traumatic brain injury and protective role of interferon-gamma: A cohort study.Cerebral circulation - cognition and behavior · 2026Article
- Serum Nrf2 Levels in Severe Traumatic Brain Injury Patients and Its Significance in Predicting 28-Day Mortality.Brain and behavior · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to examine the levels of serum Nrf2 in patients with severe traumatic brain injury (STBI) and assess its predictive value for 28-day mortality.
methodsThis study prospectively observed 252 patients with STBI who were admitted to our ICU between January 2018 and April 2024. Serum samples were collected within 24 h of admission, and levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and inflammatory cytokines were measured using ELISA. Additionally, the mortality rate within 28 days after admission to the ICU was recorded.
resultsIn this prospective observational study, based on the 28-day mortality after admission to the ICU, the patients were categorized into two groups based on their outcomes: the survival group (n = 184) and the deceased group (n = 68). Compared to the survival group, the deceased group exhibited lower serum Nrf2 levels and higher IL-6 and IL-17 levels. Spearman correlation analysis revealed a negative correlation between serum Nrf2 levels and serum IL-6, IL-1β, and IL-17 levels, while a positive correlation was observed between serum Nrf2 levels and GCS scores. The ROC curve indicated that serum Nrf2 could be used to predict the 28-day mortality in patients with STBI. Finally, multivariate logistic regression analysis showed that serum Nrf2, IL-6, and IL-17 levels were independently associated with 28-day mortality in STBI patients.
conclusionIn conclusion, we observed significantly lower serum Nrf2 levels in deceased STBI patients compared to the survival group. Additionally, Nrf2 could be used as a potential marker to predict 28-day mortality in STBI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.